♥
ISIN : INE829A01014
NSE : BIOFILCHEM
BSE : 524396
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 0.44
EPS (TTM) : 0.39
Price to Earning (P/E) : 93.55
Book Value : 11.19
Price to Bookvalue (P/B) : 3.68
Dividend Yield : 0 %
Return on Equity (ROE) : 4.00 %
Return on Capital Employed (ROCE) : 4.97 %
Biofil Chemicals & Pharmaceuticals Limited
ISIN : INE829A01014
NSE : BIOFILCHEM
BSE : 524396
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 0.44
EPS (TTM) : 0.39
Price to Earning (P/E) : 93.55
Book Value : 11.19
Price to Bookvalue (P/B) : 3.68
Dividend Yield : 0 %
Return on Equity (ROE) : 4.00 %
Return on Capital Employed (ROCE) : 4.97 %
Biofil Chemicals share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 27.99 - 27.52 -1.7 % |
| Low / High | 27.4 - 28.7 4.7 % |
| Trade Volume | 1,923 |
| 52 Week Low / High | 25.6 - 56.36 120.2 % |
-
YOU MAY ALSO LIKE
- High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Stock market course tutorial
Stock Market Investment Course explained in simple words. - Share Market basics for beginners
Share Market jargons in simple terms - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CONSOLIDATED QUARTERLY RESULT FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 16.45 | 123.06 | 26.2 | 14.94 | 136.16 | 24.34 | 173.68 | 50.32 | 152.03 | 84.43 |
| Total Income | 16.76 | 123.22 | 26.43 | 15.18 | 136.49 | 24.58 | 173.99 | 50.59 | 156.08 | 84.73 |
| Total Expenditure | 15.04 | 119.28 | 24.65 | 12.67 | 132.09 | 20.15 | 171.29 | 48.39 | 152.36 | 81.35 |
| Other Income | 0.3 | 0.17 | 0.24 | 0.24 | 0.33 | 0.25 | 0.32 | 0.28 | 4.06 | 0.29 |
| Operating Profit | 1.72 | 3.94 | 1.78 | 2.51 | 4.4 | 4.43 | 2.7 | 2.2 | 3.72 | 3.38 |
| Interest | 0.1 | 0.11 | 0.11 | 0.11 | 0.1 | 0.11 | 0.1 | 0.21 | 0.11 | |
| PBDT | 1.62 | 3.83 | 1.67 | 2.4 | 4.3 | 4.32 | 2.6 | 2.2 | 3.51 | 3.27 |
| Depreciation | 1.19 | 1.07 | 1.07 | 1.07 | 1.08 | 1.07 | 1.07 | 1.07 | 0.77 | 0.99 |
| Profit Before Tax | 0.43 | 2.76 | 0.6 | 1.33 | 3.22 | 3.25 | 1.53 | 1.13 | 2.74 | 2.28 |
| Tax | 0.72 | 0.69 | 0.15 | 0.34 | 1.14 | 0.8 | 0.3 | 0.2 | 0.26 | 0.59 |
| Profit After Tax | -0.29 | 2.07 | 0.45 | 0.99 | 2.08 | 2.45 | 1.23 | 0.93 | 2.48 | 1.69 |
| Net Profit | -0.29 | 2.07 | 0.45 | 0.99 | 2.08 | 2.45 | 1.23 | 0.93 | 2.48 | 1.69 |
| Equity Capital | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | -0.02 | 0.13 | 0.03 | 0.06 | 0.13 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
| Diluted Eps After Extraordinary Items | -0.01 | 0.13 | 0.03 | 0.06 | 0.07 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
| Diluted Eps Before Extraordinary Items | -0.01 | 0.13 | 0.03 | 0.06 | 0.07 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
STANDALONE QUARTERLY RESULT FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 16.45 | 123.06 | 26.2 | 14.94 | 136.16 | 24.34 | 173.68 | 50.32 | 152.03 | 84.43 |
| Total Income | 16.76 | 123.22 | 26.43 | 15.18 | 136.49 | 24.58 | 173.99 | 50.59 | 156.08 | 84.73 |
| Total Expenditure | 15.04 | 119.28 | 24.65 | 12.67 | 132.09 | 20.15 | 171.29 | 48.39 | 152.36 | 81.35 |
| Other Income | 0.3 | 0.17 | 0.24 | 0.24 | 0.33 | 0.25 | 0.32 | 0.28 | 4.06 | 0.29 |
| Operating Profit | 1.72 | 3.94 | 1.78 | 2.51 | 4.4 | 4.43 | 2.7 | 2.2 | 3.72 | 3.38 |
| Interest | 0.1 | 0.11 | 0.11 | 0.11 | 0.1 | 0.11 | 0.1 | 0.21 | 0.11 | |
| PBDT | 1.62 | 3.83 | 1.67 | 2.4 | 4.3 | 4.32 | 2.6 | 2.2 | 3.51 | 3.27 |
| Depreciation | 1.19 | 1.07 | 1.07 | 1.07 | 1.08 | 1.07 | 1.07 | 1.07 | 0.77 | 0.99 |
| Profit Before Tax | 0.43 | 2.76 | 0.6 | 1.33 | 3.22 | 3.25 | 1.53 | 1.13 | 2.74 | 2.28 |
| Tax | 0.72 | 0.69 | 0.15 | 0.34 | 1.14 | 0.8 | 0.3 | 0.2 | 0.26 | 0.59 |
| Profit After Tax | -0.29 | 2.07 | 0.45 | 0.99 | 2.08 | 2.45 | 1.23 | 0.93 | 2.48 | 1.69 |
| Net Profit | -0.29 | 2.07 | 0.45 | 0.99 | 2.08 | 2.45 | 1.23 | 0.93 | 2.48 | 1.69 |
| Equity Capital | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 | 162.74 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | -0.02 | 0.13 | 0.03 | 0.06 | 0.13 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
| Diluted Eps After Extraordinary Items | -0.01 | 0.13 | 0.03 | 0.06 | 0.07 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
| Diluted Eps Before Extraordinary Items | -0.01 | 0.13 | 0.03 | 0.06 | 0.07 | 0.15 | 0.08 | 0.06 | 0.15 | 0.1 |
CONSOLIDATED ANNUAL RESULT FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 223.82 | 300.35 | 400.35 |
| Total Income | 225.33 | 301.32 | 405.25 |
| Total Expenditure | 210.49 | 288.67 | 392.19 |
| Other Income | 1.5 | 0.97 | 4.9 |
| Operating Profit | 14.84 | 12.65 | 13.06 |
| Interest | 0.41 | 0.42 | 0.42 |
| PBDT | 14.43 | 12.23 | 12.64 |
| Depreciation | 4.28 | 4.29 | 3.99 |
| Profit Before Tax | 10.15 | 7.94 | 8.65 |
| Tax | 3.16 | 2.33 | 1.56 |
| Profit After Tax | 6.99 | 5.61 | 7.09 |
| Net Profit | 6.99 | 5.61 | 7.09 |
| Equity Capital | 162.74 | 162.74 | 162.74 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | -31.98 | -27.34 | -18.33 |
| Calculated EPS | 0.43 | 0.34 | 0.44 |
| Diluted Eps After Extraordinary Items | 0.44 | 0.29 | 0.44 |
| Diluted Eps Before Extraordinary Items | 0.44 | 0.29 | 0.44 |
STANDALONE ANNUAL RESULT FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 223.82 | 300.35 | 400.35 |
| Total Income | 225.33 | 301.32 | 405.25 |
| Total Expenditure | 210.49 | 288.67 | 392.19 |
| Other Income | 1.5 | 0.97 | 4.9 |
| Operating Profit | 14.84 | 12.65 | 13.06 |
| Interest | 0.41 | 0.42 | 0.42 |
| PBDT | 14.43 | 12.23 | 12.64 |
| Depreciation | 4.28 | 4.29 | 3.99 |
| Profit Before Tax | 10.15 | 7.94 | 8.65 |
| Tax | 3.16 | 2.33 | 1.56 |
| Profit After Tax | 6.99 | 5.61 | 7.09 |
| Net Profit | 6.99 | 5.61 | 7.09 |
| Equity Capital | 162.74 | 162.74 | 162.74 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | -31.98 | -27.34 | -18.33 |
| Calculated EPS | 0.43 | 0.34 | 0.44 |
| Diluted Eps After Extraordinary Items | 0.44 | 0.29 | 0.44 |
| Diluted Eps Before Extraordinary Items | 0.44 | 0.29 | 0.44 |
CONSOLIDATED PROFIT / LOSS FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 35.75 Cr | 22.38 Cr | 30.04 Cr | 40.04 Cr |
| Sales | 33.95 Cr | 21.82 Cr | 30.04 Cr | 40.04 Cr |
| Job Work/ Contract Receipts | 1.8 Cr | 56.2 Lk | 0 | 0 |
| Net Sales | 35.75 Cr | 22.38 Cr | 30.04 Cr | 40.04 Cr |
| Increase/Decrease in Stock | -2.77 Cr | 3.59 Cr | -20.13 Lk | -27.25 Lk |
| Raw Material Consumed | 35.2 Cr | 15.87 Cr | 27.62 Cr | 37.78 Cr |
| Opening Raw Materials | 54 Lk | 42.46 Lk | 96.11 Lk | 67.76 Lk |
| Purchases Raw Materials | 6.74 Cr | 2.8 Cr | 3.63 Cr | 6.31 Cr |
| Closing Raw Materials | 42.46 Lk | 96.11 Lk | 67.76 Lk | 1.73 Cr |
| Other Direct Purchases / Brought in cost | 28.34 Cr | 13.6 Cr | 23.71 Cr | 32.52 Cr |
| Power & Fuel Cost | 28.83 Lk | 30.28 Lk | 32.93 Lk | 37.69 Lk |
| Electricity & Power | 28.83 Lk | 30.28 Lk | 32.93 Lk | 37.69 Lk |
| Employee Cost | 75.16 Lk | 78.67 Lk | 62.38 Lk | 49.64 Lk |
| Salaries, Wages & Bonus | 64.31 Lk | 68.03 Lk | 54.21 Lk | 40.59 Lk |
| Contributions to EPF & Pension Funds | 5.38 Lk | 5.27 Lk | 4.77 Lk | 5.58 Lk |
| Workmen and Staff Welfare Expenses | 1.63 Lk | 1.07 Lk | 58,000 | 40,000 |
| Other Manufacturing Expenses | 30.05 Lk | 14.58 Lk | 15.93 Lk | 31.16 Lk |
| Processing Charges | 16.02 Lk | 2.9 Lk | 17,000 | 6,000 |
| Repairs and Maintenance | 5.56 Lk | 5.6 Lk | 4.88 Lk | 15.36 Lk |
| General and Administration Expenses | 29.11 Lk | 29.68 Lk | 23.62 Lk | 40.89 Lk |
| Insurance | 1.63 Lk | 1.34 Lk | 71,000 | 1.15 Lk |
| Printing and stationery | 41,000 | 41,000 | 57,000 | 74,000 |
| Professional and legal fees | 21.09 Lk | 22.22 Lk | 18.11 Lk | 18.27 Lk |
| Traveling and conveyance | 3.41 Lk | 3.19 Lk | 3.58 Lk | 2.89 Lk |
| Selling and Distribution Expenses | 86,000 | 74,000 | 1.62 Lk | 1.16 Lk |
| Advertisement & Sales Promotion | 70,000 | 74,000 | 1 Lk | 1.16 Lk |
| Sales Commissions & Incentives | 16,000 | 0 | 62,000 | 0 |
| Miscellaneous Expenses | 8.43 Lk | 4.97 Lk | 7.95 Lk | 10.59 Lk |
| Total Expenditure | 34.15 Cr | 21.05 Cr | 28.87 Cr | 39.22 Cr |
| Other Income | 79.99 Lk | 15.03 Lk | 9.7 Lk | 48.97 Lk |
| Interest Received | 2.14 Lk | 2.1 Lk | 16,000 | 67,000 |
| Profit on sale of Fixed Assets | 27,000 | 0 | 0 | 0 |
| Operating Profit | 2.4 Cr | 1.48 Cr | 1.26 Cr | 1.31 Cr |
| Interest | 6.81 Lk | 4.06 Lk | 4.25 Lk | 4.15 Lk |
| Bank Charges etc | 39,000 | 16,000 | 6,000 | 20,000 |
| PBDT | 2.33 Cr | 1.44 Cr | 1.22 Cr | 1.26 Cr |
| Depreciation | 41.19 Lk | 42.75 Lk | 42.91 Lk | 39.94 Lk |
| Profit Before Taxation & Exceptional Items | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Profit Before Tax | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Provision for Tax | 67.75 Lk | 31.65 Lk | 23.26 Lk | 15.61 Lk |
| Current Income Tax | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Deferred Tax | 35.44 Lk | 4.02 Lk | 1.14 Lk | -8.79 Lk |
| Profit After Tax | 1.24 Cr | 69.84 Lk | 56.04 Lk | 70.92 Lk |
| Consolidated Net Profit | 1.24 Cr | 69.84 Lk | 56.04 Lk | 70.92 Lk |
| Profit Balance B/F | -35.01 Cr | -33.8 Cr | -33.1 Cr | -32.54 Cr |
| Appropriations | -33.77 Cr | -33.1 Cr | -32.54 Cr | -31.83 Cr |
| Other Appropriation | -46,000 | 0 | 0 | 0 |
| Earnings Per Share | 0.76 | 0.43 | 0.34 | 0.44 |
| Adjusted EPS | 0.76 | 0.43 | 0.34 | 0.44 |
STANDALONE PROFIT / LOSS FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 35.75 Cr | 22.38 Cr | 30.04 Cr | 40.04 Cr |
| Sales | 33.95 Cr | 21.82 Cr | 30.04 Cr | 40.04 Cr |
| Job Work/ Contract Receipts | 1.8 Cr | 56.2 Lk | 0 | 0 |
| Net Sales | 35.75 Cr | 22.38 Cr | 30.04 Cr | 40.04 Cr |
| Increase/Decrease in Stock | -2.77 Cr | 3.59 Cr | -20.13 Lk | -27.25 Lk |
| Raw Material Consumed | 35.2 Cr | 15.87 Cr | 27.62 Cr | 37.78 Cr |
| Opening Raw Materials | 54 Lk | 42.46 Lk | 96.11 Lk | 67.76 Lk |
| Purchases Raw Materials | 6.74 Cr | 2.8 Cr | 3.63 Cr | 6.31 Cr |
| Closing Raw Materials | 42.46 Lk | 96.11 Lk | 67.76 Lk | 1.73 Cr |
| Other Direct Purchases / Brought in cost | 28.34 Cr | 13.6 Cr | 23.71 Cr | 32.52 Cr |
| Power & Fuel Cost | 28.83 Lk | 30.28 Lk | 32.93 Lk | 37.69 Lk |
| Electricity & Power | 28.83 Lk | 30.28 Lk | 32.93 Lk | 37.69 Lk |
| Employee Cost | 75.16 Lk | 78.67 Lk | 62.38 Lk | 49.64 Lk |
| Salaries, Wages & Bonus | 64.31 Lk | 68.03 Lk | 54.21 Lk | 40.59 Lk |
| Contributions to EPF & Pension Funds | 5.38 Lk | 5.27 Lk | 4.77 Lk | 5.58 Lk |
| Workmen and Staff Welfare Expenses | 1.63 Lk | 1.07 Lk | 58,000 | 40,000 |
| Other Manufacturing Expenses | 30.05 Lk | 14.58 Lk | 15.93 Lk | 31.16 Lk |
| Processing Charges | 16.02 Lk | 2.9 Lk | 17,000 | 6,000 |
| Repairs and Maintenance | 5.56 Lk | 5.6 Lk | 4.88 Lk | 15.36 Lk |
| General and Administration Expenses | 29.11 Lk | 29.68 Lk | 23.62 Lk | 40.89 Lk |
| Insurance | 1.63 Lk | 1.34 Lk | 71,000 | 1.15 Lk |
| Printing and stationery | 41,000 | 41,000 | 57,000 | 74,000 |
| Professional and legal fees | 21.09 Lk | 22.22 Lk | 18.11 Lk | 18.27 Lk |
| Traveling and conveyance | 3.41 Lk | 3.19 Lk | 3.58 Lk | 2.89 Lk |
| Selling and Distribution Expenses | 86,000 | 74,000 | 1.62 Lk | 1.16 Lk |
| Advertisement & Sales Promotion | 70,000 | 74,000 | 1 Lk | 1.16 Lk |
| Sales Commissions & Incentives | 16,000 | 0 | 62,000 | 0 |
| Miscellaneous Expenses | 8.43 Lk | 4.97 Lk | 7.95 Lk | 10.59 Lk |
| Total Expenditure | 34.15 Cr | 21.05 Cr | 28.87 Cr | 39.22 Cr |
| Other Income | 79.99 Lk | 15.03 Lk | 9.7 Lk | 48.97 Lk |
| Interest Received | 2.14 Lk | 2.1 Lk | 16,000 | 67,000 |
| Profit on sale of Fixed Assets | 27,000 | 0 | 0 | 0 |
| Operating Profit | 2.4 Cr | 1.48 Cr | 1.26 Cr | 1.31 Cr |
| Interest | 6.81 Lk | 4.06 Lk | 4.25 Lk | 4.15 Lk |
| Bank Charges etc | 39,000 | 16,000 | 6,000 | 20,000 |
| PBDT | 2.33 Cr | 1.44 Cr | 1.22 Cr | 1.26 Cr |
| Depreciation | 41.19 Lk | 42.75 Lk | 42.91 Lk | 39.94 Lk |
| Profit Before Taxation & Exceptional Items | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Profit Before Tax | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Provision for Tax | 67.75 Lk | 31.65 Lk | 23.26 Lk | 15.61 Lk |
| Current Income Tax | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Deferred Tax | 35.44 Lk | 4.02 Lk | 1.14 Lk | -8.79 Lk |
| Profit After Tax | 1.24 Cr | 69.84 Lk | 56.04 Lk | 70.92 Lk |
| Consolidated Net Profit | 1.24 Cr | 69.84 Lk | 56.04 Lk | 70.92 Lk |
| Profit Balance B/F | -35.01 Cr | -33.8 Cr | -33.1 Cr | -32.54 Cr |
| Appropriations | -33.77 Cr | -33.1 Cr | -32.54 Cr | -31.83 Cr |
| Other Appropriation | -46,000 | 0 | 0 | 0 |
| Earnings Per Share | 0.76 | 0.43 | 0.34 | 0.44 |
| Adjusted EPS | 0.76 | 0.43 | 0.34 | 0.44 |
CONSOLIDATED CASH FLOW FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Adjustment | 48.46 Lk | 47.82 Lk | 37.5 Lk | 63.3 Lk |
| Changes In working Capital | -61.49 Lk | -1.4 Cr | -1.05 Cr | 1.05 Cr |
| Cash Flow after changes in Working Capital | 1.79 Cr | 9.65 Lk | 12.07 Lk | 2.55 Cr |
| Cash Flow from Operating Activities | 1.11 Cr | -21.99 Lk | -11.18 Lk | 2.39 Cr |
| Cash Flow from Investing Activities | -9.61 Lk | -6.99 Lk | -1.06 Lk | -2.29 Lk |
| Cash Flow from Financing Activitie | -83.03 Lk | -58,000 | 1.51 Lk | -12.49 Lk |
| Net Cash Inflow / Outflow | 18.45 Lk | -29.56 Lk | -10.73 Lk | 2.25 Cr |
| Opening Cash & Cash Equivalents | 25.6 Lk | 44.05 Lk | 14.49 Lk | 3.76 Lk |
| Closing Cash & Cash Equivalent | 44.05 Lk | 14.49 Lk | 3.76 Lk | 2.28 Cr |
STANDALONE CASH FLOW FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 1.92 Cr | 1.01 Cr | 79.3 Lk | 86.53 Lk |
| Adjustment | 48.46 Lk | 47.82 Lk | 37.5 Lk | 63.3 Lk |
| Changes In working Capital | -61.49 Lk | -1.4 Cr | -1.05 Cr | 1.05 Cr |
| Cash Flow after changes in Working Capital | 1.79 Cr | 9.65 Lk | 12.07 Lk | 2.55 Cr |
| Cash Flow from Operating Activities | 1.11 Cr | -21.99 Lk | -11.18 Lk | 2.39 Cr |
| Cash Flow from Investing Activities | -9.61 Lk | -6.99 Lk | -1.06 Lk | -2.29 Lk |
| Cash Flow from Financing Activitie | -83.03 Lk | -58,000 | 1.51 Lk | -12.49 Lk |
| Net Cash Inflow / Outflow | 18.45 Lk | -29.56 Lk | -10.73 Lk | 2.25 Cr |
| Opening Cash & Cash Equivalents | 25.6 Lk | 44.05 Lk | 14.49 Lk | 3.76 Lk |
| Closing Cash & Cash Equivalent | 44.05 Lk | 14.49 Lk | 3.76 Lk | 2.28 Cr |
CONSOLIDATED BALANCE SHEET FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Equity - Authorised | 20 Cr | 20 Cr | 20 Cr | 20 Cr |
| Equity - Issued | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Equity Paid Up | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | -14.46 Lk | 56.39 Lk | 1.03 Cr | 1.93 Cr |
| Securities Premium | 1.73 Cr | 1.73 Cr | 1.73 Cr | 1.73 Cr |
| Profit & Loss Account Balance | -33.77 Cr | -33.1 Cr | -32.54 Cr | -31.83 Cr |
| General Reserves | 0 | 31.9 Cr | 31.9 Cr | 31.9 Cr |
| Reserve excluding Revaluation Reserve | -14.46 Lk | 56.39 Lk | 1.03 Cr | 1.93 Cr |
| Shareholder's Funds | 16.13 Cr | 16.84 Cr | 17.3 Cr | 18.2 Cr |
| Deferred Tax Assets / Liabilities | 35.62 Lk | 39.98 Lk | 37.87 Lk | 35.54 Lk |
| Deferred Tax Assets | 37,000 | 1.91 Lk | 3.08 Lk | 3.99 Lk |
| Deferred Tax Liability | 35.99 Lk | 41.89 Lk | 40.95 Lk | 39.53 Lk |
| Total Non-Current Liabilities | 35.62 Lk | 39.98 Lk | 37.87 Lk | 35.54 Lk |
| Trade Payables | 15.85 Cr | 59.63 Lk | 12.65 Cr | 27.55 Cr |
| Sundry Creditors | 15.85 Cr | 59.63 Lk | 12.65 Cr | 27.55 Cr |
| Other Current Liabilities | 14.38 Lk | 16.28 Lk | 32.33 Lk | 29.07 Lk |
| Advances received from customers | 0 | 0 | 0 | 14.41 Lk |
| Short Term Borrowings | 42.98 Lk | 46.47 Lk | 52.23 Lk | 43.89 Lk |
| Short Term Provisions | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Provision for Tax | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Total Current Liabilities | 16.75 Cr | 1.49 Cr | 13.73 Cr | 28.52 Cr |
| Total Liabilities | 33.24 Cr | 18.73 Cr | 31.41 Cr | 47.08 Cr |
| Gross Block | 11.55 Cr | 11.62 Cr | 11.63 Cr | 11.65 Cr |
| Less: Accumulated Depreciation | 1.77 Cr | 2.2 Cr | 2.63 Cr | 3.03 Cr |
| Net Block | 9.78 Cr | 9.42 Cr | 9 Cr | 8.62 Cr |
| Long Term Loans & Advances | 0 | 0 | 0 | 5.09 Lk |
| Total Non-Current Assets | 9.78 Cr | 9.42 Cr | 9 Cr | 8.68 Cr |
| Inventories | 4.34 Cr | 1.29 Cr | 1.21 Cr | 2.55 Cr |
| Raw Materials | 42.46 Lk | 96.11 Lk | 67.76 Lk | 1.73 Cr |
| Work-in Progress | 9.5 Lk | 10.35 Lk | 0 | 0 |
| Finished Goods | 3.82 Cr | 22.58 Lk | 53.06 Lk | 80.31 Lk |
| Stores and Spare | 6,000 | 28,000 | 52,000 | 1.26 Lk |
| Sundry Debtors | 17.22 Cr | 7.17 Cr | 20.5 Cr | 33.03 Cr |
| Debtors more than Six months | 0 | 3.83 Cr | 5.82 Cr | 11.59 Cr |
| Debtors Others | 17.22 Cr | 3.38 Cr | 14.77 Cr | 21.56 Cr |
| Cash and Bank | 44.05 Lk | 14.49 Lk | 3.77 Lk | 2.28 Cr |
| Cash in hand | 97,000 | 8.49 Lk | 2.6 Lk | 9.26 Lk |
| Balances at Bank | 43.08 Lk | 6 Lk | 1.17 Lk | 2.19 Cr |
| Other Current Assets | 1.1 Cr | 50.12 Lk | 38.38 Lk | 3.57 Lk |
| Prepaid Expenses | 1.37 Lk | 24.79 Lk | 14.69 Lk | 94,000 |
| Short Term Loans and Advances | 36 Lk | 20 Lk | 26.74 Lk | 50.95 Lk |
| Advances recoverable in cash or in kind | 5.19 Lk | 0 | 0 | 29.92 Lk |
| Advance income tax and TDS | 0 | 20 Lk | 26.74 Lk | 0 |
| Total Current Assets | 23.46 Cr | 9.31 Cr | 22.4 Cr | 38.41 Cr |
| Net Current Assets (Including Current Investments) | 6.71 Cr | 7.82 Cr | 8.68 Cr | 9.88 Cr |
| Total Assets | 33.24 Cr | 18.73 Cr | 31.41 Cr | 47.08 Cr |
| Total Debt | 42.98 Lk | 46.47 Lk | 52.23 Lk | 43.89 Lk |
| Book Value | 9.91 | 10.35 | 10.63 | 11.19 |
| Adjusted Book Value | 9.91 | 10.35 | 10.63 | 11.19 |
STANDALONE BALANCE SHEET FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Equity - Authorised | 20 Cr | 20 Cr | 20 Cr | 20 Cr |
| Equity - Issued | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Equity Paid Up | 16.27 Cr | 16.27 Cr | 16.27 Cr | 16.27 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | -14.46 Lk | 56.39 Lk | 1.03 Cr | 1.93 Cr |
| Securities Premium | 1.73 Cr | 1.73 Cr | 1.73 Cr | 1.73 Cr |
| Profit & Loss Account Balance | -33.77 Cr | -33.1 Cr | -32.54 Cr | -31.83 Cr |
| General Reserves | 0 | 31.9 Cr | 31.9 Cr | 31.9 Cr |
| Reserve excluding Revaluation Reserve | -14.46 Lk | 56.39 Lk | 1.03 Cr | 1.93 Cr |
| Shareholder's Funds | 16.13 Cr | 16.84 Cr | 17.3 Cr | 18.2 Cr |
| Deferred Tax Assets / Liabilities | 35.62 Lk | 39.98 Lk | 37.87 Lk | 35.54 Lk |
| Deferred Tax Assets | 37,000 | 1.91 Lk | 3.08 Lk | 3.99 Lk |
| Deferred Tax Liability | 35.99 Lk | 41.89 Lk | 40.95 Lk | 39.53 Lk |
| Total Non-Current Liabilities | 35.62 Lk | 39.98 Lk | 37.87 Lk | 35.54 Lk |
| Trade Payables | 15.85 Cr | 59.63 Lk | 12.65 Cr | 27.55 Cr |
| Sundry Creditors | 15.85 Cr | 59.63 Lk | 12.65 Cr | 27.55 Cr |
| Other Current Liabilities | 14.38 Lk | 16.28 Lk | 32.33 Lk | 29.07 Lk |
| Advances received from customers | 0 | 0 | 0 | 14.41 Lk |
| Short Term Borrowings | 42.98 Lk | 46.47 Lk | 52.23 Lk | 43.89 Lk |
| Short Term Provisions | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Provision for Tax | 32.75 Lk | 27.1 Lk | 23 Lk | 24 Lk |
| Total Current Liabilities | 16.75 Cr | 1.49 Cr | 13.73 Cr | 28.52 Cr |
| Total Liabilities | 33.24 Cr | 18.73 Cr | 31.41 Cr | 47.08 Cr |
| Gross Block | 11.55 Cr | 11.62 Cr | 11.63 Cr | 11.65 Cr |
| Less: Accumulated Depreciation | 1.77 Cr | 2.2 Cr | 2.63 Cr | 3.03 Cr |
| Net Block | 9.78 Cr | 9.42 Cr | 9 Cr | 8.62 Cr |
| Long Term Loans & Advances | 0 | 0 | 0 | 5.09 Lk |
| Total Non-Current Assets | 9.78 Cr | 9.42 Cr | 9 Cr | 8.68 Cr |
| Inventories | 4.34 Cr | 1.29 Cr | 1.21 Cr | 2.55 Cr |
| Raw Materials | 42.46 Lk | 96.11 Lk | 67.76 Lk | 1.73 Cr |
| Work-in Progress | 9.5 Lk | 10.35 Lk | 0 | 0 |
| Finished Goods | 3.82 Cr | 22.58 Lk | 53.06 Lk | 80.31 Lk |
| Stores and Spare | 6,000 | 28,000 | 52,000 | 1.26 Lk |
| Sundry Debtors | 17.22 Cr | 7.17 Cr | 20.5 Cr | 33.03 Cr |
| Debtors more than Six months | 0 | 3.83 Cr | 5.82 Cr | 11.59 Cr |
| Debtors Others | 17.22 Cr | 3.38 Cr | 14.77 Cr | 21.56 Cr |
| Cash and Bank | 44.05 Lk | 14.49 Lk | 3.77 Lk | 2.28 Cr |
| Cash in hand | 97,000 | 8.49 Lk | 2.6 Lk | 9.26 Lk |
| Balances at Bank | 43.08 Lk | 6 Lk | 1.17 Lk | 2.19 Cr |
| Other Current Assets | 1.1 Cr | 50.12 Lk | 38.38 Lk | 3.57 Lk |
| Prepaid Expenses | 1.37 Lk | 24.79 Lk | 14.69 Lk | 94,000 |
| Short Term Loans and Advances | 36 Lk | 20 Lk | 26.74 Lk | 50.95 Lk |
| Advances recoverable in cash or in kind | 5.19 Lk | 0 | 0 | 29.92 Lk |
| Advance income tax and TDS | 0 | 20 Lk | 26.74 Lk | 0 |
| Total Current Assets | 23.46 Cr | 9.31 Cr | 22.4 Cr | 38.41 Cr |
| Net Current Assets (Including Current Investments) | 6.71 Cr | 7.82 Cr | 8.68 Cr | 9.88 Cr |
| Total Assets | 33.24 Cr | 18.73 Cr | 31.41 Cr | 47.08 Cr |
| Total Debt | 42.98 Lk | 46.47 Lk | 52.23 Lk | 43.89 Lk |
| Book Value | 9.91 | 10.35 | 10.63 | 11.19 |
| Adjusted Book Value | 9.91 | 10.35 | 10.63 | 11.19 |
FINANCIAL RATIOS (CONSOLIDATED) FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 0.76 | 0.43 | 0.34 | 0.44 |
| CEPS(Rs) | 1.02 | 0.69 | 0.61 | 0.68 |
| Book NAV/Share(Rs) | 9.91 | 10.35 | 10.63 | 11.19 |
| Tax Rate(%) | 35.31 | 31.19 | 29.33 | 18.04 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 4.47 | 5.95 | 3.89 | 2.04 |
| EBIT Margin(%) | 5.56 | 4.72 | 2.78 | 2.27 |
| Pre Tax Margin(%) | 5.37 | 4.53 | 2.64 | 2.16 |
| PAT Margin (%) | 3.47 | 3.12 | 1.87 | 1.77 |
| Cash Profit Margin (%) | 4.62 | 5.03 | 3.29 | 2.77 |
| Performance Ratios | ||||
| ROA(%) | 3.28 | 2.69 | 2.24 | 1.81 |
| ROE(%) | 8.01 | 4.24 | 3.28 | 4 |
| ROCE(%) | 12.18 | 6.23 | 4.76 | 4.97 |
| Asset Turnover(x) | 0.95 | 0.86 | 1.2 | 1.02 |
| Sales/Fixed Asset(x) | 3.11 | 1.93 | 2.58 | 3.44 |
| Working Capital/Sales(x) | 5.33 | 2.86 | 3.46 | 4.05 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.32 | 0.52 | 0.39 | 0.29 |
| Receivable days | 239.55 | 198.88 | 168.17 | 244.02 |
| Inventory Days | 30.82 | 45.97 | 15.23 | 17.15 |
| Payable days | 205.82 | 154.25 | 88.15 | 195.62 |
| Valuation Parameters | ||||
| PER(x) | 86.06 | 134.67 | 120.33 | 138.5 |
| PCE(x) | 64.62 | 83.54 | 68.15 | 88.61 |
| Price/Book(x) | 6.62 | 5.59 | 3.9 | 5.4 |
| EV/Net Sales(x) | 2.99 | 4.22 | 2.26 | 2.41 |
| EV/Core EBITDA(x) | 44.53 | 63.64 | 53.71 | 73.79 |
| EV/EBIT(x) | 53.76 | 89.42 | 81.3 | 106.29 |
| EV/CE(x) | 3.21 | 5.04 | 2.16 | 5.17 |
| M Cap / Sales | 2.99 | 4.2 | 2.25 | 2.45 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 20.41 | -37.39 | 34.19 | 33.29 |
| Core EBITDA Growth(%) | 20.26 | -38.18 | -14.73 | 3.29 |
| EBIT Growth(%) | 25.24 | -46.88 | -20.84 | 8.53 |
| PAT Growth(%) | 2.83 | -43.74 | -19.76 | 26.55 |
| EPS Growth(%) | 2.83 | -43.73 | -19.76 | 26.54 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.03 | 0.02 |
| Current Ratio(x) | 1.4 | 6.23 | 1.63 | 1.35 |
| Quick Ratio(x) | 1.14 | 5.37 | 1.54 | 1.26 |
| Interest Cover(x) | 29.18 | 26 | 19.66 | 21.85 |
| Total Debt/Mcap(x) | 0 | 0 | 0.01 | 0 |
FINANCIAL RATIOS (STANDALONE) FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 0.76 | 0.43 | 0.34 | 0.44 |
| CEPS(Rs) | 1.02 | 0.69 | 0.61 | 0.68 |
| Book NAV/Share(Rs) | 9.91 | 10.35 | 10.63 | 11.19 |
| Tax Rate(%) | 35.31 | 31.19 | 29.33 | 18.04 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 4.47 | 5.95 | 3.89 | 2.04 |
| EBIT Margin(%) | 5.56 | 4.72 | 2.78 | 2.27 |
| Pre Tax Margin(%) | 5.37 | 4.53 | 2.64 | 2.16 |
| PAT Margin (%) | 3.47 | 3.12 | 1.87 | 1.77 |
| Cash Profit Margin (%) | 4.62 | 5.03 | 3.29 | 2.77 |
| Performance Ratios | ||||
| ROA(%) | 3.28 | 2.69 | 2.24 | 1.81 |
| ROE(%) | 8.01 | 4.24 | 3.28 | 4 |
| ROCE(%) | 12.18 | 6.23 | 4.76 | 4.97 |
| Asset Turnover(x) | 0.95 | 0.86 | 1.2 | 1.02 |
| Sales/Fixed Asset(x) | 3.11 | 1.93 | 2.58 | 3.44 |
| Working Capital/Sales(x) | 5.33 | 2.86 | 3.46 | 4.05 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.32 | 0.52 | 0.39 | 0.29 |
| Receivable days | 239.55 | 198.88 | 168.17 | 244.02 |
| Inventory Days | 30.82 | 45.97 | 15.23 | 17.15 |
| Payable days | 205.82 | 154.25 | 88.15 | 195.62 |
| Valuation Parameters | ||||
| PER(x) | 86.06 | 134.67 | 120.33 | 138.5 |
| PCE(x) | 64.62 | 83.54 | 68.15 | 88.61 |
| Price/Book(x) | 6.62 | 5.59 | 3.9 | 5.4 |
| EV/Net Sales(x) | 2.99 | 4.22 | 2.26 | 2.41 |
| EV/Core EBITDA(x) | 44.53 | 63.64 | 53.71 | 73.79 |
| EV/EBIT(x) | 53.76 | 89.42 | 81.3 | 106.29 |
| EV/CE(x) | 3.21 | 5.04 | 2.16 | 5.17 |
| M Cap / Sales | 2.99 | 4.2 | 2.25 | 2.45 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 20.41 | -37.39 | 34.19 | 33.29 |
| Core EBITDA Growth(%) | 20.26 | -38.18 | -14.73 | 3.29 |
| EBIT Growth(%) | 25.24 | -46.88 | -20.84 | 8.53 |
| PAT Growth(%) | 2.83 | -43.74 | -19.76 | 26.55 |
| EPS Growth(%) | 2.83 | -43.73 | -19.76 | 26.54 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.03 | 0.02 |
| Current Ratio(x) | 1.4 | 6.23 | 1.63 | 1.35 |
| Quick Ratio(x) | 1.14 | 5.37 | 1.54 | 1.26 |
| Interest Cover(x) | 29.18 | 26 | 19.66 | 21.85 |
| Total Debt/Mcap(x) | 0 | 0 | 0.01 | 0 |
SHARE HOLDING PATTERN FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Date | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 | 46.82 |
| FII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| DII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public % | 53.10 | 53.10 | 53.10 | 53.10 | 53.10 | 53.10 | 53.10 | 53.08 | 53.10 | 53.10 |
PEER COMPARISON FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
CORPORATE ACTIONS FOR BIOFIL CHEMICALS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 13-Sep-2024 | Book Closure - A.G.M. | 24-Sep-2024 30-Sep-2024 |
| BSE 13-Sep-2024 | AGM - A.G.M. | 30-Sep-2024 30-Sep-2024 |
| BSE 08-Aug-2024 | Board Meeting - Quarterly Results | 13-Aug-2024 |
| BSE 23-May-2024 | Board Meeting - Audited Results & Quarterly Results | 30-May-2024 |
| BSE 30-Jan-2024 | Board Meeting - Quarterly Results | 06-Feb-2024 |
| BSE 01-Nov-2023 | Board Meeting - Quarterly Results | 09-Nov-2023 |
| BSE 04-Sep-2023 | Book Closure - A.G.M. | 21-Sep-2023 27-Sep-2023 |
| BSE 04-Sep-2023 | AGM - A.G.M. | 27-Sep-2023 27-Sep-2023 |
| BSE 07-Aug-2023 | Board Meeting - Quarterly Results | 14-Aug-2023 |
| BSE 23-May-2023 | Board Meeting - Audited Results | 30-May-2023 |
| BSE 07-Feb-2023 | Board Meeting - Quarterly Results | 14-Feb-2023 |
| BSE 07-Nov-2022 | Board Meeting - Quarterly Results | 14-Nov-2022 |
| BSE 13-Sep-2022 | Book Closure - A.G.M. | 23-Sep-2022 30-Sep-2022 |
| BSE 13-Sep-2022 | AGM - A.G.M. | 30-Sep-2022 30-Sep-2022 |
| BSE 02-Aug-2022 | Board Meeting - Quarterly Results | 09-Aug-2022 |
| BSE 23-May-2022 | Board Meeting - Audited Results | 30-May-2022 |
| BSE 07-Feb-2022 | Board Meeting - Quarterly Results | 14-Feb-2022 |
| BSE 08-Nov-2021 | Board Meeting - Quarterly Results | 12-Nov-2021 |
CORPORATE ANNOUNCEMENTS FOR BIOFIL CHEMICALS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under regulatin 74(5) of SEBI (Depositories and participants) regulations 2018 for quarter ended Sep 2024 |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Information regarding issue of letter of confirmation |
| BSE 01-Oct-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Combined Scrutinizer report alongwith voting results for AGM |
| BSE 30-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Summary of Proceeding of 39th AGM |
| BSE 26-Sep-2024 | Intimation FILE | Closure of Trading Window Intimation for Closure of Trading Window for quarter ended September 2024 |
| BSE 16-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation under Regulation 39(3) for stop transfer and issue of duplicate share certificate |
| BSE 14-Sep-2024 | General Announcements FILE | Announcements Under Regulation 30(5) Of SEBI (LODR) Regulations 2015 Details of persons authorized for the purpose of determining the materiality of event or information and have been authorized for making the disclosures to the Stock Exchanges |
| BSE 14-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Appointment of Ms. Anisha Mangal (ACS) 70128 as a Company Secretary and Compliance officer of the Company w.e.f. 14th September 2024 |
| BSE 14-Sep-2024 | General Announcements FILE | Appointment of Company Secretary and Compliance Officer Appointment of Ms. Anisha Mangal (ACS: 70128) as a Company Secretary and Compliance officer of the Company w.e.f. 14th September 2024 |
| BSE 05-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication News paper publication for Information of dispatch of Notice of AGM and Annual report to the members |
| BSE 04-Sep-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Inegrated Annual report of Company |
| BSE 04-Sep-2024 | General Announcements FILE | Information Under Regulation 44 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 And Section 108 Of The Companies Act 2013 Regarding Voting Through Electronic Mode For The 39Th Annual General Meeting To Be Held On Monday 30Th September 2024. Information under Regulation 44 of SEBI (LODR) regulation 2015 and section 108 of Companies Act 2013 for evoting |
| BSE 04-Sep-2024 | Intimation FILE | Intimation Of Book Closure For The Purpose Of 39Th AGM Intimation of Book Closure for the purpose of 39th AGM |
| BSE 04-Sep-2024 | Intimation FILE | Notice Of 39Th AGM Notice of 39th AGM |
| BSE 30-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication regarding intimation of AGM of the COmpany scheduled to be held on 30th September 2024 and informing shareholders manner of registration of email |
| BSE 14-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication A copy of extracts of an unaudited results for the quarter ended 30th June 2024 published in Newspapers dated 14th August 2024 |
| BSE 13-Aug-2024 | General Announcements FILE | Continuous Disclosure Under Sub-Para 1 Of Para A Of Part A Of Schedule III Of The SEBI (LODR) Regulations 2015 Read With SEBI Circular SEBI/HO/CFD/CFD-Pod-1/P/CIR/2023/123 Dated 13Th July 2023 Entering in to agreement for sale transfer otherwise dispotal of undertaking subject to approval of members |
| BSE 13-Aug-2024 | Outcome FILE | Un-Audited Financial Results Of The Company For The Quarter Ended On 30Th June 2024 Along With Limited Review Report Thereon Un-audited financial results for the quarter ended 30th June 2024 |
| BSE 13-Aug-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday 13Th August 2024 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Outcome of Board Meeting held on Tuesday 13th August 2024 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
| BSE 08-Aug-2024 | Intimation FILE | Board Meeting Intimation for Intimation For Meeting Of Board Of The Directors To Be Held On Tuesday 13Th August 2024 Pursuant To The Regulation 29 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 BIOFIL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Intimation for meeting of Board of the Directors to be held on Tuesday 13th August 2024 pursuant to the Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 |
| BSE 10-Jul-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate of Compliance under Regulation 74(5) of SEBI (Depository and Participants) Regulations 2018 for the quarter ended 30th June 2024. |
| BSE 03-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 we wish to inform that Ms. Shweta Verma has tendered her resignation vide her resignation letter dated 03.07.2024 from the post of Company Secretary and Compliance Officer of the Company. |
| BSE 27-Jun-2024 | Intimation FILE | Closure of Trading Window The trading window for dealing in securities of the Company shall remain closed for all the Designated Persons their immediate relatives and connected persons (as defined in the code) w.e.f. Monday July 01 2024 for the purpose of Consideration of Un-Audited Financial Results for the quarter ended June 30 2024. |
| BSE 31-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of Publication of Financial Results in the Newspaper Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015. |
| BSE 30-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Reappointment of Secretarial Auditor for F.Y. 2024-25. |
| BSE 30-May-2024 | Outcome FILE | Audited Results For Quarter And Year Ended 31.03.2024 Audited Results for Quarter and Year Ended 31.03.2024. |
| BSE 30-May-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday 30Th May 2024 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 01/2024-2025) held on today i.e. Thursday 30th Day of May 2024 has inter alia considered and approved the Businesses as enclosed in the attachment. |
| BSE 24-May-2024 | Compliance FILE | Compliances-Reg.24(A)-Annual Secretarial Compliance Submission of Annual Secretarial Compliance Report for the Financial Year ended 31st March 2024. |
| BSE 22-May-2024 | Intimation FILE | Board Meeting Intimation for Intimation For Meeting Of Board Of The Directors (Serial No.01/2024-25) Of The Company Scheduled To Be Held On Thursday 30Th May 2024 Pursuant To The Regulation 29 Of SEBI (LODR) Regulations 2015. BIOFIL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve Audited Financial Results for the fourth Quarter as well as financial year ended on 31st March 2024 along with Auditors Report thereon and Other routine matters with the permission of the chair. |
| BSE 08-May-2024 | General Announcements FILE | Intimation To Shareholders Holding Shares In Physical Mode For Updating Of Valid PAN KYC Nomination And Other Details The Company hereby submits draft intimation letter sent to holders of physical shares of the Company for updating PAN KYC Nomination and other details in accordance with applicable SEBI Circulars in terms of provisions of Reg. 30 of SEBI (LODR) Regulations 2015 as amended from time to time. |
INSIDER TRADING FOR BIOFIL CHEMICALS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 11-Mar-2024 11-Mar-2024 | Sell Gift | 87,200 @ 0.00 (0.53 %) | SANDEEP SHAH |
| BSE 11-Mar-2024 11-Mar-2024 | Buy Gift | 87,200 @ 0.00 (0.00 %) | MANALI SIMON |
| BSE 26-Jun-2023 26-Jun-2023 | Buy Gift | 42,440 @ 0.00 (0.26 %) | SANDEEP SHAH |
| BSE 26-Jun-2023 26-Jun-2023 | Sell Gift | 127,319 @ 0.00 (0.78 %) | SMITESH SHAH |
| BSE 26-Jun-2023 26-Jun-2023 | Buy Gift | 42,440 @ 0.00 (0.26 %) | KETAN SHAH |
| BSE 26-Jun-2023 26-Jun-2023 | Buy Gift | 42,439 @ 0.00 (0.26 %) | MEENA SHAH |
| BSE 31-Mar-2022 31-Mar-2022 | Sell Gift | 300,000 @ 0.00 (1.84 %) | RAMESH SHAH |
| BSE 31-Mar-2022 31-Mar-2022 | Buy Gift | 300,000 @ 0.00 (0.00 %) | Niyati Shah |
| BSE 01-Sep-2021 01-Sep-2021 | Buy Others | 52,680 @ 0.00 (0.33 %) | MEENA SHAH |
BULK BLOCK DEALS FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 13-Sep-2024 | Sell BULK | 202,887 @ 79.50 | ANKITA VISHAL SHAH |
| BSE 13-Sep-2024 | Buy BULK | 90,010 @ 79.50 | MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED |
| BSE 13-Sep-2024 | Sell BULK | 40,010 @ 79.07 | MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED |
| BSE 13-Sep-2024 | Buy BULK | 2,887 @ 76.99 | ANKITA VISHAL SHAH |
| BSE 19-Dec-2023 | Buy BULK | 500 @ 63.25 | DB (INTL) OWN TRADING |
| BSE 19-Dec-2023 | Sell BULK | 114,000 @ 63.42 | DB (INTL) OWN TRADING |
| BSE 11-Jan-2022 | Buy BULK | 25,405 @ 96.60 | DB (INTL) OWN TRADING |
| BSE 11-Jan-2022 | Sell BULK | 83,403 @ 97.59 | DB (INTL) OWN TRADING |
DIVIDEND BY BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
No dividend details found
SPLIT / BONUS BY BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
